ClinicalTrials.Veeva

Menu

Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal Cord

R

Radiation Therapy Oncology Group

Status and phase

Completed
Phase 3

Conditions

Head and Neck Cancer

Treatments

Radiation: radiation therapy

Study type

Interventional

Funder types

NETWORK
NIH

Identifiers

NCT00002727
CDR0000064597
RTOG-9512

Details and patient eligibility

About

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective in treating patients with stage II cancer of the vocal cord.

PURPOSE: Randomized phase III trial to compare two regimens of radiation therapy in treating patients who have stage II cancer of the vocal cord.

Full description

OBJECTIVES:

  • Compare the local response rate in patients with stage II invasive squamous cell carcinoma of the true vocal cord treated with hyperfractionation vs conventional fractionation radiotherapy.
  • Compare the acute and late toxic effects of these regimens in this patient population.
  • Compare the overall and disease-free survival patterns in this patient population treated with these regimens.

OUTLINE: This is a randomized study. Patients are stratified according to substage (T2a vs T2b). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo conventional radiotherapy 5 days a week for 5 weeks followed by boost radiotherapy 5 days a week for 2 weeks.
  • Arm II: Patients undergo hyperfractionation radiotherapy 5 days a week for 5 weeks followed by boost radiotherapy 5 days a week for 1.6 weeks.

Patients with biopsy-proven persistent disease at least 6 weeks after completion of radiotherapy undergo salvage surgery with neck dissection (at the discretion of the surgeon).

Patients are followed at 4 weeks, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 240 patients will be accrued for this study within 3.2 years.

Enrollment

250 patients

Sex

All

Ages

18 to 120 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

  • Histologically proven invasive squamous cell carcinoma of the true vocal cord

    • Stage II (T2a/b N0) disease with bulk of tumor present on vocal cord (i.e., the epicenter) with extension to adjacent areas
  • No verrucal carcinoma or adenocarcinoma

  • No extension to pre-epiglottic space or pyriform sinus

  • No fixed cord or cartilage invasion

  • No evidence of adenopathy, including any of the following:

    • Nodes larger than 1 cm by radiography
    • Nodes containing a low central density consistent with necrosis by radiography
    • Clinically palpable nodes larger than 1 cm and firm in consistency
  • No recurrent or persistent disease

  • No evidence or suspicion of distant metastases

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Karnofsky 60-100%

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • Not specified

Renal:

  • Not specified

Other:

  • No other malignancy within the past 5 years except nonmelanomatous skin cancer
  • Not pregnant or nursing
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • No prior chemotherapy

Endocrine therapy:

  • Not specified

Radiotherapy:

  • No prior radiotherapy to the mid-neck or larynx

Surgery:

  • No prior complete stripping or laser excision of all gross disease

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

250 participants in 2 patient groups

Radiation therapy - conventional fractionation
Active Comparator group
Description:
Radiation therapy - conventional fractionation (70 Gy/2 Gy once per day/7 Weeks) 35 fractions
Treatment:
Radiation: radiation therapy
Radiation therapy - hyperfractionation
Experimental group
Description:
Radiation therapy - hyperfractionation (79.2 Gy/1.2 b.i.d/6.5 weeks) 66 fractions
Treatment:
Radiation: radiation therapy

Trial contacts and locations

237

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems